USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences (USNA) — director Form 4 activity. On 10/23/2025, 1,057 shares of common stock were acquired via the vesting/settlement of restricted stock units (code M). To cover taxes, 606 shares were withheld/disposed at $20.63 (code F). Following these transactions, the director directly owned 4,586 shares. The related RSU award had a $0 exercise price and continues to vest in scheduled 25% installments on specified dates.
USANA Health Sciences (USNA) reported an insider transaction by a director on 10/23/2025. The filing shows the conversion of restricted stock units into 1,057 shares of common stock (Transaction Code M) and a separate Code F disposition of 265 shares at $20.63 per share.
Following these transactions, the reporting person directly held 9,027 shares of common stock and 2,115 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) reported an insider stock acquisition by a director. On 10/23/2025, the director acquired 1,057 shares of common stock through the settlement of restricted stock units, coded M (derivative conversion).
The shares were delivered at a stated price of $0. Following the transaction, the director beneficially owns 7,986 shares directly, with 2,115 RSUs remaining outstanding. Each RSU represents the right to receive one share of USNA common stock. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed a Form 4 showing a director acquired 1,057 shares of common stock on 10/23/2025 via transaction code M, reflecting the settlement of restricted stock units into shares.
Following the transaction, the director beneficially owned 7,698 common shares directly. The filing also shows 2,115 restricted stock units beneficially owned after the event, with vesting scheduled at 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The derivative security price is listed as $0, consistent with RSU settlement.
USANA Health Sciences (USNA) reported a director’s acquisition of 1,057 shares of common stock on 10/23/2025, coded “M” for settlement of restricted stock units.
After the transaction, the reporting person beneficially owns 1,057 shares directly and 2,115 restricted stock units. The RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed an insider transaction by a director on 10/23/2025. The filing reports the acquisition of 1,057 shares of common stock via the settlement of restricted stock units (Transaction Code M). Following the transaction, the reporting person directly owns 6,315 common shares and holds 2,115 restricted stock units.
The RSUs vest in four equal installments of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The RSU settlement carried a stated price of $0 for the underlying common shares, consistent with equity award vesting mechanics.
USANA Health Sciences (USNA) disclosed insider activity dated 10/23/2025. A director acquired 1,057 shares of common stock through the conversion of restricted stock units (code M) and disposed of 476 shares (code F) at $20.63.
After the transactions, the director beneficially owned 5,918 common shares directly and held 2,115 restricted stock units. These RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences furnished an update on investor communications. The company announced a press release with financial results for the third quarter ended September 27, 2025, and said it will post a “Management Commentary” on its website. Executives will host a conference call with brief remarks followed by Q&A, with webcast and telephone access details provided.
The press release and Management Commentary are included as Exhibits 99.1 and 99.2 and are furnished, not filed. These materials will be available on www.usana.com.
USANA Health Sciences, Inc. filed a current report to let investors know it has released a press release with preliminary financial results for its third quarter ended September 27, 2025. The company is furnishing this information under the sections covering results of operations and Regulation FD, and it attaches the press release as Exhibit 99.1. The disclosure is classified as “furnished” rather than “filed,” which limits its use for certain legal purposes but still makes the preliminary quarterly results publicly available.
Dimensional Fund Advisors LP reports holding 915,049 shares of USANA Health Sciences Inc common stock, representing 5.0% of the class. The filing states that the reported shares are owned by investment funds advised or sub‑advised by Dimensional, which disclaims beneficial ownership and says the holdings are managed in the ordinary course of business and not for the purpose of changing or influencing control. Of the reported shares, Dimensional asserts sole voting power over 887,817 shares and sole dispositive power over 915,049 shares; no shared voting or dispositive power is reported.
The statement clarifies these holdings arise from Dimensional’s advisory roles to registered investment companies, commingled funds, group trusts and separate accounts and that no single Fund listed is known to hold more than 5% of the class. The filing includes the required certification by Dimensional’s compliance officer.